Otsuka America completes its takeover of Transcend Therapeutics, a biotech company dedicated to exploring novel medicines for post-traumatic stress disorder (PTSD). As per the agreement, Otsuka paid a total consideration amounting to $700 million, including potential additional payments of $525 million based on future product sales. Transcend Therapeutics will function as a wholly owned subsidiary of Otsuka America. Of great importance in the deal is the lead asset of Transcend, TSND-201 (methylone), which is a rapid-acting neuroplastogen that has shown promise in treating PTSD. It is estimated that more than 13 million patients suffer from PTSD annually in the US. There has not been any new FDA approval for PTSD in 25 years; thus, TSND-201 has previously shown positive results in the Phase 2 IMPACT-1 trial and is under further evaluation in a Phase 3 trial.
Also Read: Enphase Energy Introduces IQ9N Microinverter to Boost Residential Solar Performance
This drug candidate is recognized as a breakthrough therapy by the US FDA and has been nominated for priority vouchers in accessing psychedelics. “This marks an important step forward in our continued commitment to patients and their families in need of more treatment options for serious mental illness,” said Tarek Rabah, president and CEO, Otsuka North America Pharmaceutical Business. “By combining Otsuka’s decades of expertise in central nervous system disorders with Transcend’s pioneering approach, we are well positioned to accelerate the development of new treatment options for those who continue to face significant unmet needs.” The acquisition further strengthens Otsuka’s neuroscience portfolio while positioning the company to advance innovative, science-driven therapies for patients living with PTSD and other complex mental health conditions.